Strikingly, even the combination of a BRAF and a MEK inhibitor, which is the new standard of care treatment in patients with BRAFV600E-mutated melanoma, did not alter SOX10 expressions levels [2, 5, 6]. Here, MAP2K7 is linked to melanoma.